https://www.selleckchem.com/pr....oducts/gilteritinib-
Injection of EGFR-19del tumor-derived exosomes promoted LLC tumor progression and induced immunosuppression. The combination of gefitinib and GM-CSF treatment recovered tumor T cell infiltration in EGFR-19del tumors by rescuing the function of DCs and increasing the efficacy of anti-PD-L1 treatment. Together, these results indicated that LC with the EGFR E746-A750 deletion mutation induced anergic DCs to repress antitumor immunity through exosomes.Poly(ADP-ribose)-polymerase (PARP)-1 and PARP-2 play an essential role in the
Like
Comment
Share
